1018 related articles for article (PubMed ID: 28222768)
1. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
3. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
4. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
Resende U; Cabello C; Ramalho SOB; Zeferino LC
BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
7. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
[TBL] [Abstract][Full Text] [Related]
8. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
9. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer.
Zenzola V; Cabezas-Quintario MA; Arguelles M; Pérez-Fernández E; Izarzugaza Y; Correa A; García-Foncillas J
Clin Transl Oncol; 2018 Nov; 20(11):1448-1454. PubMed ID: 29671222
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
13. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
14. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
17. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study.
Balmativola D; Marchiò C; Maule M; Chiusa L; Annaratone L; Maletta F; Montemurro F; Kulka J; Figueiredo P; Varga Z; Liepniece-Karele I; Cserni G; Arkoumani E; Amendoeira I; Callagy G; Reiner-Concin A; Cordoba A; Bianchi S; Decker T; Gläser D; Focke C; van Diest P; Grabau D; Lips E; Wesseling J; Arisio R; Medico E; Wells C; Sapino A
Breast Cancer Res Treat; 2014 Dec; 148(3):511-23. PubMed ID: 25395316
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
20. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
